Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lacosamide
Drug ID BADD_D01238
Description Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. Recent studies indicate that Lacosamide only affects those neurons which are depolarized or active for long periods of time, typical of neurons at the focus of an epileptic seizure, as opposed to other antiepileptic drugs such as carbamazepine or lamotrigine which slow the recovery from inactivation and reduce the ability of neurons to fire action potentials.
Indications and Usage Lacosamide is indicated for adjunctive therapy for partial onset seizures in patients with epilepsy over 17 years old. Injection is indicated for short term use when oral therapy is not feasible.
Marketing Status approved
ATC Code N03AX18
DrugBank ID DB06218
KEGG ID D07299
MeSH ID D000078334
PubChem ID 219078
TTD Drug ID D05OFX
NDC Product Code 73289-0063; 73289-0064; 14445-012; 66651-914; 16714-549; 27808-246; 0131-5410; 47335-918; 50228-193; 51407-721; 51991-348; 51991-349; 60687-698; 65162-923; 65162-926; 68083-480; 68462-680; 69539-026; 72865-235; 36998-1810; 0904-7244; 65977-0075; 14445-132; 31722-627; 31722-814; 31722-815; 0131-2479; 42291-862; 47335-980; 53746-925; 66689-108; 69543-455; 70710-1886; 0904-7246; 0904-7247; 65372-1186; 0131-2478; 47335-922; 53746-926; 60687-676; 65862-749; 66689-109; 67877-736; 68462-678; 68462-681; 62332-173; 65862-747; 12828-0087; 14445-021; 42765-060; 65862-720; 68225-057; 14445-129; 14445-130; 31722-813; 60505-0405; 62332-171; 65219-204; 65862-748; 69367-350; 72603-140; 13612-0021; 0904-7245; 50370-0024; 66039-882; 27808-244; 31722-812; 0131-1810; 46708-171; 47335-943; 50228-192; 62332-172; 62332-174; 69367-348; 70771-1682; 36998-2478; 16714-552; 27808-245; 0131-2480; 42291-860; 42934-303; 46708-172; 46708-173; 51407-722; 51991-351; 60687-687; 67877-733; 67877-735; 69367-351; 69539-025; 70954-488; 36998-0119; 36998-2480; 52038-005; 53747-069; 62331-062; 16714-548; 25021-791; 31722-203; 0121-1012; 0121-2024; 46708-174; 51991-350; 65162-924; 65162-925; 66689-107; 67877-734; 69539-027; 72205-220; 72266-242; 16436-0101; 17180-2746; 36998-2477; 36998-2479; 16714-550; 53746-924; 65862-750; 66689-110; 69539-028; 73289-0065; 17205-107; 0131-2477; 42291-861; 42291-863; 50228-194; 51407-723; 51407-724; 53746-923; 68462-679; 69367-349; 70710-1359; 14445-131; 14445-406; 27808-243; 50228-195
UNII 563KS2PQY5
Synonyms Lacosamide | Vimpat | N-benzyl-2-acetamido-3-methoxypropionamide | N benzyl 2 acetamido 3 methoxypropionamide | N-benzyl-AcMeOPrNH2 | N benzyl AcMeOPrNH2
Chemical Information
Molecular Formula C13H18N2O3
CAS Registry Number 175481-36-4
SMILES CC(=O)NC(COC)C(=O)NCC1=CC=CC=C1
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tic17.02.05.024; 19.11.04.0010.004973%-
Tinnitus04.04.01.002; 17.04.07.0040.003657%
Tonic convulsion17.12.03.0110.001463%-
Toxic epidermal necrolysis10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.008--
Tremor17.01.06.0020.040808%
Urinary retention20.02.02.0110.004388%
Urticaria10.01.06.001; 23.04.02.001--
Venous injury12.01.11.009; 24.11.03.001--
Ventricular fibrillation02.03.04.0080.005851%
Ventricular tachycardia02.03.04.0100.004388%
Vertigo04.04.01.003; 17.02.12.0020.006874%
Vision blurred06.02.06.007; 17.17.01.010--
Visual acuity reduced06.02.10.012; 17.17.01.0110.003949%
Vomiting07.01.07.003--
Mental status changes19.07.01.0010.006436%-
Tubulointerstitial nephritis20.05.02.0020.001463%-
Acute generalised exanthematous pustulosis10.01.01.034; 11.07.01.018; 12.03.01.005; 23.03.10.0020.001463%-
Balance disorder08.01.03.081; 17.02.02.0070.019014%-
Bradyphrenia17.03.03.004; 19.10.03.0020.002194%-
Contusion12.01.06.001; 15.03.05.007; 23.03.11.002; 24.07.06.001--
Tonic clonic movements17.12.03.0060.001463%-
Cytokine release syndrome10.02.01.0100.001463%
Oscillopsia06.02.06.0090.001463%-
Lymphatic disorder01.09.01.003---
Protein urine present13.13.02.006---
Inappropriate antidiuretic hormone secretion05.03.03.001; 14.05.07.0010.005119%-
Secretion discharge08.01.03.0190.001463%-
Type IV hypersensitivity reaction10.01.03.022---
Electrocardiogram PR prolongation13.14.05.012---
Affect lability19.04.01.001---
The 8th Page    First    Pre   8 9 10    Next   Last    Total 10 Pages